
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. demonstrates a compelling growth trajectory, with its TissueCypher test volume experiencing a substantial 92% year-over-year increase and a 23% quarter-over-quarter increase in the second quarter of 2025. This surge in test volume is anticipated to be bolstered by ongoing expansions to the sales force, with expectations for the gastrointestinal sales team to reach maturity in the second half of 2025, which suggests enhanced sales and operational efficiency. Additionally, the company has improved the gross margin of its TissueCypher test over time, underscoring its ability to enhance profitability alongside revenue growth, particularly when compared to slower growth in its DecisionDx-Melanoma product.
Bears say
Castle Biosciences Inc. faces a negative outlook primarily due to anticipated lower EV-to-estimated revenue multiples for its dermatology and DecisionDx-UM tests compared to its TissueCypher product. The reliance on the DecisionDx-Melanoma for revenue generation poses a risk, as most of the company's income stems from this single product line, making it vulnerable to market fluctuations. Despite appearing significantly undervalued based on current levels and conservative estimates, these factors indicate potential challenges in achieving sustainable revenue growth and maintaining investor confidence.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares